POG's Personal Perspectives

Gynecologic Oncology Group Study 229C: Personal Reflection

Author: Kimberly K. Leslie (University of Iowa)

  • Gynecologic Oncology Group Study 229C: Personal Reflection

    POG's Personal Perspectives

    Gynecologic Oncology Group Study 229C: Personal Reflection

    Author:

Abstract

I heard the statistician say, “The drug does not have sufficient activity to study further in this population.” It was my co-investigator on GOG study 229C, Gefitinib in the Treatment of Advanced and Recurrent Endometrial Cancer (see related extended abstract in this issue*), calling from Roswell Park in Buffalo. He had just completed the analysis of data from 26 women treated on our study – a study which had been five years in the making from concept to clinical trial.

Keywords: Clinical trials, gefitinib

How to Cite:

Leslie, K. K., (2013) “Gynecologic Oncology Group Study 229C: Personal Reflection”, Proceedings in Obstetrics and Gynecology 3(4), 1–2. doi: https://doi.org/10.17077/2154-4751.1223

Rights: Copyright © Kimberly K. Leslie, 2013.

Downloads:
Download pdf
View PDF

204 Views

214 Downloads

Published on
04 Nov 2013
License
CC BY 3.0